Unknown

Dataset Information

0

Comparative studies on the therapeutic benefit of targeted ?-particle radiation therapy for the treatment of disseminated intraperitoneal disease.


ABSTRACT: Identification of the appropriate combination of radionuclide, target and targeting vehicle is critical for successful radioimmunotherapy. For the treatment of disseminated peritoneal diseases such as pancreatic or ovarian cancer, ?-emitting radionuclides have been proposed for targeted radiation therapy. This laboratory has taken a systematic approach investigating targeted ?-radiation therapy, allowing comparisons to now be made between 211At, 227Th, 213Bi and 212Pb. Herein, trastuzumab radiolabeled with 211At and 227Th was evaluated for therapeutic efficacy in the LS-174T i.p. tumor model. A dose escalation study was conducted with each radioimmunoconjugate (RIC). Therapeutic benefit was realized with 211At-trastuzumab with doses of 20, 30 and 40 ?Ci. At doses >40 ?Ci, toxicity was observed with greater weight loss and 2-fold higher decrease in the platelet counts. Following a second study comparing the effect of 20, 30 and 40 ?Ci of 211At-trastuzumab, 30 ?Ci was selected as the dose for future studies. A parallel study was performed evaluating 0.25, 0.5, 1.0, 2.0 and 5.0 ?Ci of 227Th-trastuzumab. The 0.5 and 1.0 ?Ci injected dose resulted in a therapeutic response; a lower degree of weight loss was experienced by the mice in the 0.5 ?Ci cohort. When the data is normalized for comparing 211At, 227Th, 213Bi and 212Pb, the choice of radionuclide for RIT is perhaps not entirely based on simple therapeutic efficacy, other factors may play a role in choosing the "right" radionuclide.

SUBMITTER: Milenic DE 

PROVIDER: S-EPMC5664163 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.

Milenic Diane E DE   Baidoo Kwamena E KE   Kim Young-Seung YS   Barkley Rachel R   Brechbiel Martin W MW  

Dalton transactions (Cambridge, England : 2003) 20171001 42


Identification of the appropriate combination of radionuclide, target and targeting vehicle is critical for successful radioimmunotherapy. For the treatment of disseminated peritoneal diseases such as pancreatic or ovarian cancer, α-emitting radionuclides have been proposed for targeted radiation therapy. This laboratory has taken a systematic approach investigating targeted α-radiation therapy, allowing comparisons to now be made between <sup>211</sup>At, <sup>227</sup>Th, <sup>213</sup>Bi and  ...[more]

Similar Datasets

| S-EPMC3563752 | biostudies-other
2011-01-14 | E-GEOD-21059 | biostudies-arrayexpress
2011-01-14 | GSE21059 | GEO
2016-05-04 | GSE81067 | GEO
| S-EPMC6930656 | biostudies-literature
| S-EPMC7792624 | biostudies-literature
| S-EPMC5522122 | biostudies-other
| S-EPMC7162423 | biostudies-literature